ARPI evidence in the absence of head-to-head trials

Martin Schoen, MD, PhD, discusses how clinicians can interpret comparative real-world evidence and indirect analyses when head-to-head ARPI data are unavailable.

Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.